CD8A and neoplasm: As expected, CD8+ T cell depletion in LTX-315-treated mice did not prevent initial BP tumor control in the days that followed LTX-315 administration (first phase of response); however, it triggered significantly faster tumor re-growth (second phase of response) (Fig. 3G).